Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
Bermúdez-Pirela V, Souki A, Cano-Ponce C, Bermúdez-Arias F, Mengual-Moreno E, Leal-Gonzalez E, Lemus-Antepaz M, de Bravo MC, de Díaz AA, de Pirela NL, Cano-Peñaloza R, Puche-Medina G, Arraiz N, Reyna-Villazmil N, Contreras F, Israili ZH, Valasco M.
Am J Ther. 2007 Mar-Apr;14(2):213-20. doi: 10.1097/01.pap.0000249920.70815.2d.
[Etofylline clofibrate in the treatment of diabetic dyslipidemia: results of a 6-month period of therapy].
Rajecová E, Klimes I, Seböková E, Rychnavská E, Pleváková L, Linke-Cvrkalová A, Langrová H.
Vnitr Lek. 1995 Oct;41(10):677-81.
